New Zealand to list BioMarin's Naglazyme for mucopolysaccharidosis VI

17 March 2016

Following consultations last month, New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with Australian subsidiary of US biotech firm BioMarin Pharmaceuticals’ (Nasdaq: BMRN) to list galsulfase (Naglazyme) for people with mucopolysaccharidosis (MPS) VI in the Pharmaceutical Schedule.

No changes were made to the proposal following consultation. In summary, the effect of the decision is that Naglazyme) will be funded in the community under Special Authority criteria and in DHB hospitals subject to restrictions. Listing in the Pharmaceutical Schedule would occur subject to Medsafe approval of the pharmaceutical.

Galsulfase is the second medicine funded as a result of the Medicines for Rare Disorders Request for Proposals process.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK